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HIV-1 superinfection (SI) occurs when an infected individual acquires a distinct new viral strain. The rate of superinfection may
be reflective of the underlying HIV risk in a population. The Centre for the AIDS Programme of Research in South Africa
(CAPRISA) 004 clinical trial demonstrated that women who used a tenofovir-containing microbicide gel had lower rates of HIV
infection than women using a placebo gel. Women who contracted HIV-1 during the trial were screened for the occurrence of
superinfection by next-generation sequencing of the viral gag and env genes. There were two cases (one in each trial arm) of sub-
type C superinfection identified from the 76 women with primary infection screened at two time points (rate of superinfection,
1.5/100 person-years). Both women experienced a >0.5-log increase in viral load during the window when superinfection oc-
curred. The rate of superinfection was significantly lower than the overall primary HIV incidence in the microbicide trial (inci-
dence rate ratio [IRR], 0.20; P  0.003). The women who seroconverted during the trial reported a significant increase in sexual
contact with their stable partner 4 months after seroconversion (P < 0.001), which may have lowered the risk of superinfection
in this population. The lower frequency of SI compared to the primary incidence is in contrast to a report from a general hetero-
sexual African population but agrees with a study of high-risk women in Kenya. A better understanding of the rate of HIV super-
infection could have important implications for ongoing HIV vaccine research.
HIV superinfection (SI) occurs when an infected individualacquires a new viral strain that is phylogenetically distinct
from all previous viral strains (1, 2). This can include both inter-
and intrasubtype SI, and it has been reported in a variety of pop-
ulations around the world (3). The rates at which HIV SI occurs
differ between populations and appear to be related, in part, to the
underlying primary HIV incidence rate (2–5). Previous analysis of
high-risk women in Kenya found a significantly lower rate of SI
compared to primary incidence (6). HIV SI can significantly im-
pact HIV disease markers by increasing the HIV viral load tempo-
rarily or lastingly, by possibly accelerating disease progression,
and by putatively increasing HIV-specific antibody responses (3,
4, 7, 8).
The Centre for the AIDS Programme of Research in South
Africa (CAPRISA) 004 clinical trial demonstrated for the first time
that an antiretroviral microbicide gel could help to prevent HIV
infection in women (9). The rates of primary HIV incidence were
relatively high in the full trial population (7.3 per 100 person-years
[py]) as well as in both the tenofovir (5.6/100 py) and the placebo
(9.1/100 py) arms (9). Women in the CAPRISA 004 trial were
followed monthly for 2 years and were provided at each visit with
counseling, condoms, and treatment for any other sexually trans-
mitted infections. Women who seroconverted during the
CAPRISA 004 trial were initially followed monthly and then every
3 months in the CAPRISA 002 acute infection cohort study, and
they were offered treatment through their local AIDS treatment
center or the CAPRISA AIDS treatment program once their CD4
count dropped to 350 cells/l (10). This study examined if HIV
SI as identified by next-generation sequencing (NGS) of the viral
population occurred at a rate similar to the primary incidence in
the trial.
MATERIALS AND METHODS
The CAPRISA 004 study population has been described in detail (9).
Briefly, viral genetic sequences were generated for 76 women who sero-
converted to HIV and who had plasma samples available within the first 3
months of infection (median time from infection, 10 weeks; interquartile
range [IQR], 9 to 11 weeks) and had an available sample at their last visit
prior to the initiation of antiretroviral therapy (ART) or at the end of the
study (median time from infection, 110.5 weeks; IQR, 70 to 123 weeks).
All women who seroconverted during the trial stopped using the vaginal
gel regardless of the study arm. The CAPRISA 004 trial and the CAPRISA
002 study were both approved by the Biomedical Research Ethics Com-
mittee of the University of KwaZulu-Natal, and all of the subjects pro-
vided informed consent to have their samples used for future studies.
Subject samples were examined for SI as previously described (2).
Briefly, viral RNA was extracted from the plasma samples, reverse
transcribed, and amplified in a nested-PCR format for a region of the
viral p24 (390 bp) and gp41 (324 bp) genes. Samples that amplified
for both time points in at least one region were sequenced using the
454 platform (Roche, Branford, CT) (1, 2). The resulting sequencing
reads were analyzed using the GS Amplicon Variant Analyzer, version
2.5 (Roche). All sequence reads were compared, and similar sequences
were combined into a single consensus sequence. Consensus se-
quences that were within 10 bases from the ends of the amplicon and
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comprised a cluster of at least 10 individual near-identical sequence
reads were determined (1, 2). These consensus sequences were used for
all subsequent phylogenetic analyses (1).
HIV superinfection was defined when an individual’s follow-up sam-
ple demonstrated two or more distinct consensus sequences forming a
phylogenetically distinct cluster that was unlinked from the individual’s
consensus sequences in the initial sample and was of adequate genetic
distance from the baseline sequences to rule out natural evolutionary drift
(0.55% per year for the p24 region or 0.98% per year for the gp41
region) (1). Samples from subjects who initially were identified by their
initial and follow-up samples as being superinfected were further analyzed
at multiple midpoints (selected from samples between months 3 to 6, 9 to
12, 12 to 24, and 24 to 36) to verify SI and to identify the approximate time
of SI. The time of SI was estimated to be the midpoint between the first
time point that contained the SI strain and the last sample with amplifiable
sequences that did not show a presence of the SI strain. Primary HIV
incidence rates were previously calculated as part of the CAPRISA 004 trial
(9). Briefly, women were tested monthly with two HIV-1/-2 rapid tests,
and positive samples were confirmed with two separate positive viral load
tests. The samples from the previous month were then screened for acute
HIV infection (9). The SI incidence rate was calculated as the total number
of SI events identified during the total follow-up between the closest sam-
ples tested.
The NGS consensus sequences for gp41 and p24 are available upon
request. The total sequence reads and consensus sequences were each
compared for both genomic regions at the baseline and follow-up time
points with the Mann-Whitney rank sum test.
Sequences from the initial time point were also analyzed for the pres-
ence of initial coinfection (3). The consensus sequences were analyzed for
the presence of phylogenetically distinct viral populations with 1% ge-
netic distance between the populations. As recombination can potentially
occur rapidly following infection, consensus sequences from women who
had these diverse viral populations in either genomic region (n  7) were
further analyzed by scanning subgenomic windows of the sequences for
evidence of recombination with a distinct virus. Any regions with 50 bp
that were no more similar to the main viral quasispecies than they were to
one of a reference panel of 23 region appropriate sequences were flagged
as potential recombinant regions. The phylogenies of these regions were
then reconstructed in order to verify the presence of phylogenetically
unlinked viral sequences.
Sexual partner status (stable versus casual) at the visit immediately
prior to the estimated date of infection, near the initial time point
screened, and 10 months postinfection (IQR, 9.4 to 10.7 months) for the
women screened was calculated to examine the possible behavioral risk
factors for SI.
HIV viral loads were measured at each monthly visit as described
previously (with the Roche Cobas TaqMan HIV-1 monitor v1.0 or Taq-
Man version 2.0; Roche Diagnostics, Branchburg, NJ) (9). The rates of SI
and primary incidence were calculated as previously described (2, 9). In-
cidence rate ratios (IRRs) were calculated using STATA 12 (College Sta-
tion, TX) using a univariate Poisson model.
RESULTS
NGS for at least one region of the viral genome was performed on
samples from 76/96 (79.2%) women who seroconverted during
the trial from the first 3 months of infection (median time from
infection, 10 weeks; IQR, 9 to 11 weeks) and from a later sample
prior to the initiation of antiretroviral therapy (ART) (median
time from infection, 110.5 weeks; IQR, 70 to 123 weeks) (Table 1).
There was no significant difference by trial arm in the percentage
of women whose samples were successfully sequenced (tenofovir,
29/35 [82.9%], versus placebo, 47/61 [77.0%]; P  0.68). The total
sequence reads and consensus sequences for the gp41 region were
not significantly different (Table 2). However, the sequence reads
and consensus sequences for the p24 region were significantly
lower for the second time point screened (P  0.001) (Table 2).
Except for one woman who was infected with HIV subtype A,
all of the seroconverters were infected with HIV subtype C. The
sequences from the sample at the first time point for each woman
were initially screened phylogenetically for the presence of possi-
ble coinfections. The consensus sequences from samples that had
distinct phylogenetic populations (1%) in either genomic re-
gion (n  7) were further analyzed by scanning the sequences for
the presence of distinctly different regions. Two cases of possible
coinfection were identified, and in these cases, evidence of recom-
binant regions derived from a phylogenetically unlinked virus was
found.
Of all the women screened, two (2.6%) were found to have
been superinfected (Fig. 1). There was one case of SI identified in
each arm of the study, and in both cases, the initial and superin-
fecting strains were subtype C. A sample from the midpoint for
each SI case was analyzed with NGS to determine the approximate
time of superinfection. The SI events occurred between 10 and 41
weeks in one case and 36 and 122 weeks in the other. In each case,
the women experienced a spike in their viral loads of at least 0.5 log
between visits during this period (Fig. 2). The rate of SI for the
seroconverters screened was calculated to be 1.5/100 py (95% con-
fidence interval [CI], 0.2 to 5.4 per 100 py), which was significantly
lower than the observed primary infection rate of 7.3/100 py ob-
served for the total trial population (IRR, 0.20, 95% CI, 0.02 to
0.75; P  0.003). The rate of SI was also significantly lower than
the rate of primary infection in the placebo (IRR, 0.16, 95% CI,
0.02 to 0.62; P  0.001) and treatment arms (IRR, 0.27, 95% CI,
0.03 to 1.03; P  0.018).
For the 96 women screened, 80 had sexual partner data avail-
able directly before seroconversion (median time to HIV infec-
tion, 14 days; IQR, 13 to 17 days) and near the first time point
screened (median time from HIV infection, 4 months; IQR, 3.5 to
4.6 months). Of these women, 64/80 (80%) reported having had
sex in the past 30 days with a stable partner at the preinfection time
point, but a significantly higher percentage of these women (79/80
[99%]) reported having had sex with a stable partner in the past 30
days at the time point near the initial SI screening sample (P 
0.001). This significant increase in reported sex with a stable part-
ner was also found at 10 months postinfection (91%; P  0.049).
There was no difference in reported sex with causal partners be-
tween the three time points; only one woman reported having had
a casual sexual contact preinfection and at 10 months, and only
two women reported having had a causal sexual partner at 4
months.
TABLE 1 Characteristics of women from the CAPRISA 004 trial
analyzed for superinfection
Population characteristics (n  76) Median IQRa
Age (yr) 22 21–26
HIV viral load (log copies/ml)a 4.7 3.9–5.2
CD4 counta 476 401–647
Follow-up (yr) 1.9 1.1–2.2
% from tenofovir arm 38.2
a Interquartile range (IQR), CD4 counts, and viral load were measured at initial time
point screened for SI (median, 10 weeks from infection).
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HIV SI has been demonstrated to occur at rates that reflect the un-
derlying rate of primary HIV infection in multiple populations span-
ning a variety of risk levels (2–4, 11, 12). Other studies have found
either significantly lower rates or no evidence of SI, but many of these
studies utilized less sensitive methods to identify SI (3, 13, 14). The
observed frequency of SI in this population enrolled in a microbicide
intervention study was significantly lower than the primary HIV in-
cidence, which was relatively high. In both cases, the women experi-
enced an increase in the viral load during the window period when
HIV SI occurred. This increase was temporary in one case and lasting
in the other, which is similar to the disparity in viral load reactions to
SI seen in other studies (3). In addition, two additional women were
identified at 3 months postinfection as being likely initially coinfected
with two strains of HIV.
This finding of a lower frequency of SI than of primary inci-
dence is in contrast to a previous finding by our group, using
identical laboratory methods, where the rate of SI was similar to
the rate of primary infection in a general population cohort in the
rural Rakai District of Uganda (1, 2). Interestingly, a study of
high-risk women in Kenya also found a significantly lower rate of
SI than primary incidence, which agrees with these findings (6).
TABLE 2 Sequence reads and consensus sequences
Time point
p24 (median [IQR]) gp41 (median [IQR])
Total reads Consensus sequences Total reads Consensus sequences
Initiala 7,472b (6,709–8,046) 50b (37–68) 9,012 (6,611–11,730) 77 (40–118)
Follow-upc 6,020b (5,274–7,135) 35b (27–46) 8,774 (6,058–12,134) 58 (39–114)
a Initial time point was a median of 10 weeks postinfection.
b Significantly higher reads and consensus sequences at the first time point (P  0.001, Mann-Whitney rank sum test).
c Follow-up time point was a median of 110.5 weeks postinfection.
FIG 1 HIV superinfection cases among CAPRISA 004 seroconverters. Phylogenetic tree of consensus gp41 viral sequences (10 reads) derived from 454
pyrosequencing of a seroconversion (red) and a follow-up sample (blue), with the superinfecting strain indicated (dashed circle). The number of repeated
sequences represented by each consensus sequence is shown at the end of the consensus identifier. Distance is indicated for the tree by the scale at bottom of the
tree, and samples are grouped with a selection of subtype reference sequences (black). Bootstrap values of 80% are indicated (1,000 replicates).
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To date, these three studies are the largest in Africa to have used
deep sequencing to examine for superinfection, and they were
distinctly different in terms of rates of primary infections and
follow-up. The rate of primary infection in the Rakai study (1.2/
100 py), which included men and women, was substantially less
than those within the CAPRISA 004 trial (7.3/100 py) and the
Kenyan trial (5.75/100 py) (2, 6, 9). The study presented here and
the Rakai study calculated IRRs in a similar manner, while the
Kenyan study utilized a slightly different hazard ratio analysis (2,
6). The Rakai study was powered to identify rates that were at least
half or double the rate of primary incidence, which limited its
ability to identify more subtle differences. In all three studies,
newly diagnosed individuals were provided with counseling and
were referred for care, but the frequency of follow-up was mark-
edly different. While individuals in the Rakai community cohort
study were followed annually, seroconverters from the CAPRISA
004 study were followed up at least once per month until 12
months postinfection and every 3 months thereafter until ART
initiation, and they continued to receive counseling at each visit.
The Kenyan study collected samples quarterly, but the women
were seen monthly (6, 15). It is possible that the continuous rein-
forcement provided by these frequent visits affected the behavior
of the women, which lowered their risk of SI.
Interestingly, only 4.3% of the women recruited into the
CAPRISA 004 trial reported having had multiple causal sexual
partners, and 95.2% reported one stable partner in the past year
(16). In the women screened for SI, there was a significant increase
in reported sexual contact with a stable partner at both 4 and 10
months after seroconversion. This would suggest that these
women may have altered their sexual habits in a way that subse-
quently lowered their risk of becoming superinfected. Therefore,
although these women were at high risk for primary infection
from their stable partners, their lack of casual partners may have
made SI less likely. It is unknown what risk factors are associated
with HIV SI in study cohorts and in the HIV-infected population
as a whole or if they are the same as those for primary HIV infec-
tion, as would be expected (3). It is difficult to extrapolate what
role HIV SI is playing in nonstudy settings and how knowledge of
SI affects the behavior of HIV-infected individuals (3). Due to the
relatively small number of cases identified here, it was not possible
to examine risk factors for HIV SI in more detail. More research in
a variety of populations is needed to fully clarify the relationship
between HIV SI risk and primary incidence.
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